Emerging drugs for chronic kidney disease

Area of Science:

• Nephrology
• Pharmacology
• Clinical Trials

Background:

• Chronic kidney disease (CKD) is a growing global health concern, with increasing incidence of end-stage renal disease (ESRD).
• Hypertension, diabetes, and an aging population contribute to the rising prevalence of CKD.
• Current treatments like ACE inhibitors and ARBs slow progression but novel therapies are needed.

Purpose of the Study:

• To review emerging drugs in Phase II or III trials for the treatment of chronic kidney disease (CKD).
• To identify promising novel pharmacological agents for slowing renal function loss.

Main Methods:

• Systematic literature review of PubMed and ClinicalTrials.gov.
• Focused on drugs in Phase II or III clinical trials for CKD.

Main Results:

• Despite high expectations, novel drug development for CKD has yielded limited success.
• Preliminary positive results in some studies require cautious interpretation due to inconsistent data.
• Agents showing promise in preclinical animal models have often been less effective in human trials.

Conclusions:

• The development of effective new drugs for managing chronic kidney disease (CKD) has faced significant challenges.
• Current evidence suggests a gap between preclinical promise and clinical efficacy for many emerging CKD therapies.
• Further rigorous research is essential to identify and validate novel treatments that can effectively slow CKD progression.